Modulation of In Vivo Tumor Oxygenation via Polymersome-encapsulated Myoglobin

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$299,888.00
Award Year:
2011
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA159527-01A1
Award Id:
n/a
Agency Tracking Number:
R43CA159527
Solicitation Year:
2011
Solicitation Topic Code:
NCI
Solicitation Number:
PA10-050
Small Business Information
A169, ASTeCC Bldg.,145 Graham Avenue, LEXINGTON, KY, 40506-0286
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
808379072
Principal Investigator:
PAIMANGHOROGHCHIAN
(267) 496-3625
ppg@vindicopharma.com
Business Contact:
PAIMANGHOROGHCHIAN
(267) 496-3625
ppg@vindicopharma.com
Research Institute:
Stub




Abstract
DESCRIPTION (provided by applicant): Over 250,000 new cases of head and neck cancers (HNCs) and non-small cell lung cancers (NSCLCs) are diagnosed every year in the United States. At the time of diagnosis, 60% of these cases are regionally advanced (stageIII and IV). Wide surgical excision is not the immediate therapeutic option for most of these locally advanced solid tumor malignancies. A number of studies have shown that a course of combined chemotherapy and radiotherapy, also known as chemoradiotherapy(CRT), promises superior results over chemotherapy or radiation therapy alone. The ability of radiation to eradicate cancer cells depends critically upon the presence of molecular oxygen, a potent radiosensitizer involved in mediating DNA damage. While low oxygen levels (hypoxia) has been recognized as a cause of treatment failure in solid tumors for more than 50 years, previous attempts to improve tumor oxygenation, including whole-body hyperbaric oxygen and systemic erythropoietin treatments, have had limited success. Vindico NanoBioTechnology, Inc. (Vindico), proposes to develop a novel nanoparticle-based therapeutic adjuvant that improves radiation and chemotherapy of HNCs, NSCLCs, as well as other solid tumor malignancies. The goal of this Phase I SBIRproject is to create nanoparticle composites that exhibit the requisite in situ properties for safe and effective in vivo oxygen delivery. In colaboration with researchers from Duke University, these agents will be tested for their ability to modulate invivo tumor oxygenation. Subsequent Phase II work will generate crucial pre-clinical animal data regarding toxicity and the ability of these novel nanoparticles to augment radiotherapy. PUBLIC HEALTH RELEVANCE: The proposed project aims to utilize nanotechnology to deliver a natural protein that increases tumor oxygen levels. This research will have a major impact on public health by resulting in a novel agent that improves cancer radiation and chemotherapy. The end result wil be increased patient survival and an enhanced standard of care. Significant additional advantages include tremendous cost savings to the health care system, in reduced operating and therapeutic costs, as well as local job creation and economic stimulus.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government